VAM
NBIX icon

Visium Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Visium Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,837
Closed -$219K – 128
2016
Q2 		$219K Sell
4,837
-1,859,385
-100% -$85.6M 0.02% 312
2016
Q1 		$73.7M Sell
1,864,222
-337,628
-15% -$13.4M 1.25% 8
2015
Q4 		$125M Buy
2,201,850
+2,345
+0.1% +$119K 1.87% 5
2015
Q3 		$87.5M Buy
2,199,505
+192,322
+10% +$9.3M 1.2% 12
2015
Q2 		$95.9M Sell
2,007,183
-1,012,694
-34% -$42.9M 1.36% 9
2015
Q1 		$120M Buy
3,019,877
+558,037
+23% +$20M 1.77% 6
2014
Q4 		$55M Buy
2,461,840
+674,579
+38% +$12.8M 0.78% 22
2014
Q3 		$28M Buy
1,787,261
+2,840
+0.2% +$42.4K 0.41% 40
2014
Q2 		$26.5M Sell
1,784,421
-216,514
-11% -$3.06M 0.41% 42
2014
Q1 		$32.2M Sell
2,000,935
-113,495
-5% -$1.94M 0.52% 36
2013
Q4 		$19.7M Buy
2,114,430
+307,293
+17% +$3M 0.39% 54
2013
Q3 		$20.5M Sell
1,807,137
-141,083
-7% -$1.94M 0.46% 52
2013
Q2 		$26.1M Buy
+1,948,220
New +$23.9M 0.61% 36

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Visium Asset Management's NBIX Position: Q3 2016 in Review

Visium Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 4,837 shares — an estimated $219K sold.

Visium Asset Management first reported a position in NBIX in Q2 2013 and held it in 13 quarters. The position peaked at $125M in Q4 2015. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • Visium Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • Visium Asset Management sold 4,837 Neurocrine Biosciences shares in Q3 2016, an estimated $219K.
  • Visium Asset Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 13 quarters.
  • Visium Asset Management's Neurocrine Biosciences position peaked at $125M in Q4 2015.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.